Andrew Bellinger
2021
In 2021, Andrew Bellinger earned a total compensation of $3.3M as Chief Scientific Officer at Verve Therapeutics, a 223% increase compared to previous year.
Compensation breakdown
| Non-Equity Incentive Plan | $310,500 |
|---|---|
| Option Awards | $2,588,979 |
| Salary | $409,583 |
| Other | $7,117 |
| Total | $3,316,179 |
Bellinger received $2.6M in option awards, accounting for 78% of the total pay in 2021.
Bellinger also received $310.5K in non-equity incentive plan, $409.6K in salary and $7.1K in other compensation.
Rankings
In 2021, Andrew Bellinger's compensation ranked 4,034th out of 12,406 executives tracked by ExecPay. In other words, Bellinger earned more than 67.5% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 4,034 out of 12,406 | 68th |
Division Manufacturing | 1,658 out of 5,494 | 70th |
Major group Chemicals And Allied Products | 686 out of 2,369 | 71st |
Industry group Drugs | 609 out of 2,090 | 71st |
Industry Pharmaceutical Preparations | 427 out of 1,537 | 72nd |
Source: SEC filing on April 29, 2022.
Bellinger's colleagues
We found two more compensation records of executives who worked with Andrew Bellinger at Verve Therapeutics in 2021.